TCON News and Press, TRACON Pharmaceuticals Inc. From 12/10/20

TRACON Pharmaceuticals ([[TCON]] +2.8%) has initiated dosing in Phase 2 ENVASARC trial, evaluating envafolimab for undifferentiated pleomorphic sarcoma or myxofibrosarcoma, type of cancer in soft tissue. Interim data is expected in mid-2021.Primary objective of this 160-subject tria...

SAN DIEGO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform t...

SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform t...

TRACON Pharmaceuticals ([[TCON]] -0.3%) and its corporate partners, Alphamab Oncology and 3D Medicines, have submitted a marketing application seeking approval for envafolimab (KN035) in MSI-H/dMMR cancer to the National Medical Products Administration in China.Envafolimab is a single-domain ...

SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform t...

Looking For Top Penny Stocks Today? Penny stocks have been some of the most interesting stocks to watch this week. Most importantly, small cap stocks, in general, have captivated traders more-so than large caps. One of the reasons has to do with a search for volatility after Monday&...

TRACON Pharmaceuticals, Inc. (TCON) Q3 2020 Earnings Conference Call November 10, 2020 4:30 PM ET Company Participants Charles Theuer - President and Chief Executive Officer Scott Brown - Chief Accounting Officer and Head of Finance Conference Call Participants Presentation Operator Good day,...

Tracon (TCON): Q3 GAAP EPS of -$0.38 beats by $0.28.Cash and cash equivalents were $26.5 million at September 30, 2020, compared to $16.4 million at December 31, 2019. We expect our current cash and cash equivalents to fund operations into the first quarter of 2022.Shares +3%.Press Relea...

SAN DIEGO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform t...

SAN DIEGO, Nov. 03, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform t...